Optimal Management of Antiplatelet Therapy and Proton Pump Inhibition Following Percutaneous Coronary Intervention

Coronary Artery Disease (PH Stone, Section Editor)

Opinion statement

Dual antiplatelet therapy (aspirin and a P2Y12 antagonist) is required after the insertion of a coronary artery stent. If the stent has been inserted in the context of an acute coronary syndrome (ACS), then clopidogrel or a high-potency P2Y12 antagonist such as prasugrel or ticagrelor should be considered. Current indications for the use of prasugrel in this situation include ST elevation, diabetes, or previous stent thrombosis on clopidogrel therapy. If the stent has been inserted electively for stable ischemic heart disease, then the patient should normally receive clopidogrel. Next, it is important to consider the patient’s bleeding risk. The CRUSADE score can be used to determine the likelihood of a subsequent gastrointestinal (GI) bleed. For patients treated with aspirin and clopidogrel who are at high risk of a GI bleed, the current evidence suggests that a proton pump inhibitor (PPI) is the most effective way to reduce this risk. There is evidence that omeprazole may attenuate the pharmacodynamic effect of clopidogrel and, therefore, it would be reasonable to use an alternative PPI that has less risk of negative pharmacokinetic and pharmacodynamic interaction, such as pantoprazole. If a patient is at moderate or low risk of bleeding, then a PPI should be avoided in combination with clopidogrel as the risk of negative interaction is greater than the risk of GI bleeding. There is no substantive evidence that PPIs attenuate the therapeutic effect of prasugrel or ticagrelor; therefore, patients at moderate or high risk of GI bleeding should be offered a PPI.

Keywords

Antiplatelet therapy clopidogrel prasugrel ticagrelor proton pump inhibitors omeprazole pantoprazole lansoprazole pantoprazole lansoprazole acute coronary syndromes 

Notes

Disclosure

M.R. Thomas: none; R.F. Storey is a consultant for AstraZeneca, Eli Lilly/Daiichi Sankyo, Novartis, Merck, The Medicines Company, Eisai, Accumetrics, and Sanofi-Aventis/Bristol-Myers Squibb; has received grants (all paid to his institution) from AstraZeneca, Eli Lilly/Daiichi Sankyo, Merck, Dynabyte, and Accumetrics; has received payments for lectures (including service on speakers’ bureaus) from AstraZeneca, Eli Lilly/Daiichi Sankyo, Merck, and GlaxoSmithKline; has received payment for manuscript preparation from AstraZeneca and Eli Lilly/Daiichi Sankyo; and has had travel/accommodations/meeting expenses covered by AstraZeneca and Eli Lilly/Daiichi Sankyo.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
  2. 2.
    Storey RF, Sanderson HM, White AE, et al. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol. 2001;110(4):925–34.CrossRefGoogle Scholar
  3. 3.
    Judge HM, Buckland RJ, Sugidachi A, et al. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thromb Haemost. 2010;103(6):1210–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–75.PubMedCrossRefGoogle Scholar
  5. 5.
    Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Pharmacology. 2010;38(1):92–9.Google Scholar
  6. 6.
    Hulot J-S, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol. 2010;56(2):134–43.PubMedCrossRefGoogle Scholar
  7. 7.
    Judge HM, Patil SB, Buckland RJ, et al. Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel. J Thromb Haemostasis: JTH. 2010;8(8):1820–7.CrossRefGoogle Scholar
  8. 8.
    Farid N, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007;81(5):735–41.PubMedCrossRefGoogle Scholar
  9. 9.
    Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet. 1996;31:9–28.PubMedCrossRefGoogle Scholar
  10. 10.
    ISIS-2 Collaborative group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet. 1998;2:349–60.Google Scholar
  11. 11.
    Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of the randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke among high risk patients. BMJ. 2002;324:71–86.CrossRefGoogle Scholar
  12. 12.
    Yusuf S, Zhao F, Mehta S. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The New England. 2001;345(7):494–502.CrossRefGoogle Scholar
  13. 13.
    Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179–89.PubMedCrossRefGoogle Scholar
  14. 14.
    Mehta DR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527–33.PubMedCrossRefGoogle Scholar
  15. 15.
    Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA: The J Am Med Assoc. 2002;288(19):2411–20.CrossRefGoogle Scholar
  16. 16.
    Mehta SR, Bassand J, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363(10):930–42.PubMedCrossRefGoogle Scholar
  17. 17.
    Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.PubMedCrossRefGoogle Scholar
  18. 18.
    Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.PubMedCrossRefGoogle Scholar
  19. 19.
    British National Formulary, http://www.bnf.org. Accessed June 2011.
  20. 20.
    Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med. 2010;152(6):337–45.PubMedGoogle Scholar
  21. 21.
    Kwok CS, Nijjar RS, Loke YK, et al. Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis. Drug Safety: An International Journal Of Medical Toxicology And Drug Experience. 2011;34(1):47–57.CrossRefGoogle Scholar
  22. 22.
    Lanas A, García-Rodríguez L, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007;102(3):507–15.PubMedCrossRefGoogle Scholar
  23. 23.
    Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation. 2009;119(14):1873–82.PubMedCrossRefGoogle Scholar
  24. 24.
    Li XQ. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 Activities. Drug Metabol Dispos. 2004;32(8):821–7.CrossRefGoogle Scholar
  25. 25.•
    Ferreiro JL, Ueno M, Tomasello SD, et al. Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. Circulation Cardiovasc Interv. 2011;4:00–0.Google Scholar
  26. 26.
    Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56(12):919–33.PubMedCrossRefGoogle Scholar
  27. 27.
    Gilard M, Arnaud B, Le Gal G, et al. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006;4(11):2508–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Siller-Matula JM, Jilma B, Schrör K, et al. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost. 2010;8:2624–41.PubMedCrossRefGoogle Scholar
  29. 29.•
    Gilard M, Arnaud B, Cornily J-C, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51(3):256–60.PubMedCrossRefGoogle Scholar
  30. 30.
    Cuisset T, Frere C, Quilici J, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol. 2009;54(13):1149–53.PubMedCrossRefGoogle Scholar
  31. 31.••
    Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65–74.PubMedCrossRefGoogle Scholar
  32. 32.
    Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemostasis. 2009;714–9.Google Scholar
  33. 33.
    Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Hear J. 2009;157(1):148.CrossRefGoogle Scholar
  34. 34.
    Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. J Am Med Assoc. 2011;305:1097–105.CrossRefGoogle Scholar
  35. 35.••
    Siller-Matula JM, Jilma B, Schrör K, et al. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemostasis 2010;2624–2641. This is the most recent meta-analysis of the association of concomitant use of PPIs with cardiovascular events in patients who are treated with clopidogrel. It showed that concomitant use of PPI was associated with a significantly increased risk of cardiovascular events. This increased risk of cardiovascular events was not seen in patients who were treated with pantoprazole.Google Scholar
  36. 36.••
    Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–17.PubMedCrossRefGoogle Scholar
  37. 37.
    Würtz M, Grove EL, Kristensen SD, et al. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart (British Cardiac Society). 2010;96(5):368–71.CrossRefGoogle Scholar
  38. 38.
    Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol. 2010;56(18):1456–62.PubMedCrossRefGoogle Scholar
  39. 39.
    O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989–97.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Cardiovascular MedicineQueen’s Medical CentreNottinghamUK
  2. 2.Cardiovascular ScienceUniversity of SheffieldSheffieldUK

Personalised recommendations